Click here for slides on this topic


TECOS

Cardiovascular safety study of the DPP-4 inhibitor, sitagliptin. TECOS is an acronym for Trial Evaluating Cardiovascular Outcomes with Sitagliptin.
The following content matched the glossary term: TECOS

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Silvio Inzucchi MD on TECOS Subanalysis No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

NDEI.org Expert Commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor Sitagliptin

Top

Vivian Fonseca provides expert insights on results of the TECOS cardiovascular safety study of the DPP-4 inhibitor, sitagliptin

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts



Slide Library Results

Search Results for: TECOS Slides Found: 14
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
Type 2 Diabetes Is Associated With Cardiovascular Outcomes | NDEI
Connection Between Type 2 Diabetes and Heart Failure PPT | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
No Heart Failure Hospitalization Risk With Sitagliptin in TECOS | NDEI
No Increased Risk of HF Hospitalization, CV Death With Sitagliptin TECOS | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI
TECOS No HF Hospitalization Risk With Sitagliptin Treatment Diabetes | NDEI